In conclusion, our new screening method, based on measurement of IGF1 levels at 3 weeks of life and the presence of sepsis during the first 3 weeks or life, allows restriction of the current AAP screening criteria, probably limiting screening to pre-term babies of <28 weeks of gestation and/or <1,100 g birth weight. This evidence concerns the gene IGF1 and Sepsis.